약학회지

ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 5.

Table. 5.

Recommendations of SGLT2 inhibitor use for heart failure in treatment guidelines from the United States, Europe, and Republic of Korea

United States (2022)14) Europe (2021)43) Republic of Korea19)
Prevention Recommendations In patients with type 2 diabetes and either established CVD or at high cardiovascular risk, SGLT2 inhibitors should be used to prevent hospitalizations for HF SGLT2 inhibitors are recommended in patients with type 2 diabetes at risk for CV events to reduce hospitalizations for HF, major CV events, end-stage renal dysfunction, and CV death None
Recommended SGLT2 inhibitors Unspecified Canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, sotagliflozin
HFrEF Recommendation SGLT2 inhibitors are recommended to reduce hospitalization for HF and cardiovascular mortality in patients with symptomatic chronic HFrEF, irrespective of presence of type 2 diabetes SGLT2 inhibitors are recommended for patients with HFrEF to reduce the risk of HF hospitalization and death
Recommended SGLT2 inhibitors Dapagliflozin, empagliflozin Dapagliflozin, empagliflozin
HFmrEF Recommendation In patients with HFmrEF, SGLT2 inhibitors can be beneficial in decreasing HF hospitalizations and cardiovascular mortality SGLT2 inhibitors not recommended
Recommended SGLT2 inhibitors Unspecified -
HFpEF Recommendation In patients with HFpEF, SGLT2 inhibitors can be beneficial in decreasing HF hospitalizations and cardiovascular mortality SGLT2 inhibitors not recommended
Recommended SGLT2 inhibitors Unspecified -

CV: cardiovascular; CVD: cardiovascular disease; HF: heart failure; HFmrEF: heart failure with mildly reduced ejection fraction; HFpEF: heart failure with preserved ejection fraction; HFrEF: heart failure with reduced ejection fraction; SGLT2: sodium-glucose cotransporter-2

Yakhak Hoeji 2022;66:175-83 https://doi.org/10.17480/psk.2022.66.4.175
© 2022 Yakhak Hoeji